Compile Data Set for Download or QSAR
Report error Found 90 Enz. Inhib. hit(s) with all data for entry = 8882
TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421861(US10493060, Example 24 | US10525036, Example 24 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421869(US10493060, Example 32 | US10525036, Example 32 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421868(US10493060, Example 31 | US10525036, Example 31 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421868(US10493060, Example 31 | US10525036, Example 31 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421867(US10493060, Example 30 | US10525036, Example 30 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421867(US10493060, Example 30 | US10525036, Example 30 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421866(US10493060, Example 29 | US10525036, Example 29 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421866(US10493060, Example 29 | US10525036, Example 29 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421865(US10493060, Example 28 | US10525036, Example 28 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421865(US10493060, Example 28 | US10525036, Example 28 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421863(US10493060, Example 26 | US10525036, Example 26 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421870(US10493060, Example 33 | US10525036, Example 33 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421860(US10493060, Example 23 | US10525036, Example 23 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421860(US10493060, Example 23 | US10525036, Example 23 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421859(US10493060, Example 22 | US10525036, Example 22 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421859(US10493060, Example 22 | US10525036, Example 22 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM120095(US8697715, 39 | US9259470, 39 | US10525036, Exampl...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421857(US10493060, Example 20 | US10525036, Example 20 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421856(US10493060, Example 19 | US10525036, Example 19 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421856(US10493060, Example 19 | US10525036, Example 19 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421855(US10493060, Example 18 | US10525036, Example 18 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421883(US10493060, Example 48 | US10525036, Example 48 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421893(US10493060, Example 58 | US10525036, Example 58 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421892(US10493060, Example 57 | US10525036, Example 57 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421891(US10493060, Example 56 | US10525036, Example 56 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421890(US10493060, Example 55 | US10525036, Example 55 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421889(US10493060, Example 54 | US10525036, Example 54 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421887(US10493060, Example 52 | US10525036, Example 52 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421886(US10493060, Example 51 | US10525036, Example 51 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421885(US10493060, Example 50 | US10525036, Example 50 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421884(US10493060, Example 49 | US10525036, Example 49 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421857(US10493060, Example 20 | US10525036, Example 20 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421882(US10493060, Example 47 | US10525036, Example 47 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421881(US10493060, Example 46 | US10525036, Example 46 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421880(US10493060, Example 45 | US10525036, Example 45 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421878(US10493060, Example 43 | US10525036, Example 43 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421877(US10493060, Example 42 | US10525036, Example 42 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421876(US10493060, Example 41 | US10525036, Example 41 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421875(US10493060, Example 40 | US10525036, Example 40 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421874(US10493060, Example 39 | US10525036, Example 39 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421873(US10493060, Example 38 | US10525036, Example 38 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421840(US10493060, Example 3 | US10525036, Example 3 | 2-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM426336(US10525036, Example 10 | (S)-2-(3-(6-Isopropoxypyr...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM426336(US10525036, Example 10 | (S)-2-(3-(6-Isopropoxypyr...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421846(US10493060, Example 9 | US10525036, Example 9 | (R...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421855(US10493060, Example 18 | US10525036, Example 18 | ...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421845(US10493060, Example 8 | US10525036, Example 8 | (S...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(US10493060, Example 7 | US10525036, Example 7 | 7-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 3(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421844(US10493060, Example 7 | US10525036, Example 7 | 7-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Recurium Ip Holdings

US Patent
LigandPNGBDBM421843(US10493060, Example 6 | US10525036, Example 6 | 7-...)
Affinity DataIC50: 50nMAssay Description:Activated ERK1 and ERK2 activity was determined in a Mobility Shift Assay (MSA) format as follows: Compound and kinase solution were prepared with as...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: